Jenburkt Pharmaceuticals Limited (NSE:JENBURPH)

Market Cap	4.24B -19.4%
Revenue (ttm)	1.71B +7.6%
Net Income	328.76M -0.4%
EPS	74.50 -0.4%
Shares Out	n/a
PE Ratio	12.80
Forward PE	n/a
Dividend	20.70 (2.17%)
Ex-Dividend Date	Aug 28, 2026

Volume	543
Open	980.00
Previous Close	974.00
Day's Range	951.20 - 980.00
52-Week Range	845.00 - 1,073.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 2, 2027

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 801
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: JENBURPH

Financial Performance

In fiscal year 2026, Jenburkt Pharmaceuticals's revenue was 1.69 billion, an increase of 11.24% compared to the previous year's 1.52 billion. Earnings were 347.36 million, an increase of 8.34%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 11, 2026

Data Sources Report a data error